

30 Jun (SUN) 2024

Venue	Room 305	Room 304
Time	Registration 07:00-16:00	
07:30-08:30	Oral Presentation	Young Investigator Award Presentation
08:30-08:55	Plenary Session (VII) <i>Therapeutic targets and clinical trials</i>	Basic and Translational Workshop
08:55-09:20		
09:20-09:45		
09:45-10:10		
10:10-10:30	Break	
10:30-10:55	Plenary Session (VIII) <i>Novel therapy and management of obesity</i>	Basic and Translational Workshop
10:55-11:20		
11:20-11:45		
11:45-12:10		
12:10-13:10	Luncheon Symposium (VI) Novo Nordisk	Luncheon Symposium (VII) Abbvie
13:10-13:30	Plenary Session (IX) <i>Cross-talk between diabetologist and hepatologist</i>	Plenary Session (X) <i>Cross-talk between cardiologist and hepatologist</i>
13:30-13:50		
13:50-14:10		
14:10-14:30		
14:30-14:50		
14:50-15:10	Break	
15:10-15:35	Plenary Session (XI) <i>Current management and systemic therapies for HCC</i>	Plenary Session (XII) <i>Policy review for MAFLD</i>
15:35-16:00		
16:00-16:25		
16:25-16:50		
16:50-17:10	Closing Ceremony	

June 30, 2024 (Sunday)

Kaohsiung Exhibition Center

Plenary Session (VII): Therapeutic targets and clinical trials				Room 305
Moderators: Jee-Fu Huang (Kaohsiung) / Takumi Kawaguchi (Kurume)				
08:30-08:55	PS7-1	What We Have Learned from the Failed Trials?	Vincent Wai-Sun Wong	Hong Kong
08:55-09:20	PS7-2	Pharmacotherapeutic Trials Achieving NASH Resolution and Beyond	Ming-Ling Chang	Taoyuan
09:20-09:45	PS7-3	Weight-lowering Drugs in Clinical Trials	Sue Pedersen	Calgary
09:45-10:10	PS7-4	The Unmet Needs and the Endpoints of NASH Clinical Trials	Philip N Newsome	Birmingham

Basic and Translational Workshop (I)				Room 304
Moderators: Yan-Hwa Wu Lee (Hsinchu) / Chia-Ho Shih (Taipei)				
08:30-08:55	BTW1-1	Animal Model for Associations between Hormones and Metabolic-Associated Fatty Liver Disease	Shiou-Hwei Yeh	Taipei
08:55-09:20	BTW1-2	Advance in the Methodology for Vasculopathy in MAFLD	Jordi Gracia Sancho	Barcelona
09:20-09:45	BTW1-3	Advances of Organoids in MAFLD	Yun-Shen Chan	Guangzhou
09:45-10:10	BTW1-4	Energy Expenditure in Fatty Liver	David E Cohen	Boston

Plenary Session (VIII): Novel therapy and management of obesity				Room 305
Moderators: Chun-Yen Lin (Taoyuan) / Diana A. Payawal (Manila)				
10:30-10:55	PS8-1	Lifestyle Modification for Obesity and Nutrition Recommendation	Meng-Chuan Huang	Kaohsiung
10:55-11:20	PS8-2	Crucial Role of Exercise in Treatment for Obesity	Sen-Fang Huang	Hualien
11:20-11:45	PS8-3	Endoscopic and Surgical Treatments for Obesity	Chi-Ming Tai	Kaohsiung
11:45-12:10	PS8-4	TBA		

Basic and Translational Workshop (II)				Room 304
Moderators: Mei-Hwei Chang (Taipei) / David E Cohen (Boston)				
10:30-10:45	BTW2-1	Metabolomics in Liver Disease	Ching-Hua Kuo	Taipei
10:45-11:00	BTW2-2	Role of Apolipoprotein J in the Progression of MAFLD	Kung-Chia Young	Tainan
11:00-11:15	BTW2-3	Resolution of liver fibrosis in NAFLD	Kuei-Chuan Lee	Taipei
11:15-11:30	BTW2-4	An Omega-6 PUFA Derived Oxilipin Prevents Diet-induced Obesity, Insulin Resistance, and Steatohepatitis in Mice	Yi-Cheng Chang	Taipei
11:30-11:45	BTW2-5	Cardiac fibrosis in NASH mice treated with GLP-1 RA and pioglitazone	Wei-Ting Chang	Kaohsiung
11:45-12:00	BTW2-6	Identification of genetic alterations during fibrogenesis in MAFLD	Chia-Hung Yen	Kaohsiung

Plenary Session (IX): Cross-talk between cardiologist and hepatologist				Room 305
Moderators: Wen-Jone Chen (Taipei) / Yen-Wen Wu (Taipei) / Pin-Nan Cheng (Tainan)/ Sheng-Nan Lu (Kaohsiung)				
13:10-13:30	PS9-1	CV Risk and Outcomes	Ki-Chul Sung	Seoul
13:30-13:50	PS9-2	Interplay among MAFLD, CV and DM	Joseph Pappachan	Preston
13:50-14:10	PS9-3	Cross-talk Between Adipose Tissue and Liver	Hung-Tsung Wu	Tainan
14:10-14:30	PS9-4	Current Guidance of MAFLD-CVD: Cardiologist's View	Yen-Wen Wu	Taipei
14:30-14:50	PS9-5	Current Guidance of MAFLD-CVD: Hepatologist's View	Pin-Nan Cheng	Tainan

June 30, 2024 (Sunday)

Kaohsiung Exhibition Center

Plenary Session (X): Cross-talk between diabetologist and hepatologist Room 304

Moderators: Chien-Ning Huang (Taichung) / Chih-Yuan Wang (Taipei) / Huey-Ling Chen (Taipei) / Rong-Nan Chien (Taoyuan)

13:10-13:30	PS10-1	The Impact of MAFLD on DM	Horng-Yih Ou	Tainan
13:30-13:50	PS10-2	The Impact of DM on MAFLD	Kathleen E Corey	Boston
13:50-14:10	PS10-3	Recent Advances in Anti-diabetes Drugs	Yi-Sun Yang	Taichung
14:10-14:30	PS10-4	Current Guidance of MAFLD-DM: Endocrinologist's View	Chih-Yuan Wang	Taipei
14:30-14:50	PS10-5	Current Guidance of MAFLD-DM: Hepatologist's View	Mohamed Rosmawati	Kuala Lumpur

Plenary Session (XI): Current management and systemic therapies for HCC Room 305

Moderators: Chai-Yen Dai (Kaohsiung) / Shuichiro Shiina (Tokyo)

15:10-15:35	PS11-1	The Impact of Steatosis on HCC Treatment	Yi-Hsiang Huang	Taipei
15:35-16:00	PS11-2	NAFLD-driven HCC: Safety and Efficacy of Current Treatment Options	Teerha Piratvisuth	Songkhla
16:00-16:25	PS11-3	Systemic Treatment of Non-viral HCC: An Asian Perspective	Stephen L Chan	Hong Kong
16:25-16:50	PS11-4	Novel Systemic Treatment for HCC	Ann-Lii Cheng	Taipei

June 30, 2024 (Sunday)

Kaohsiung Exhibition Center

Plenary Session (XII): Policy review for MAFLD				Room 304
Moderators: Pei-Jer Chen (Taipei) / Masao Omata (Tokyo)				
15:10-15:25	PS12-1	Policies and Strategy in MAFLD: West Pacific View	Chun-Jen Liu	Taipei
15:25-15:40	PS12-2	Policies and Strategy in MAFLD: East Asia View	Jian-Gao Fan	Shanghai
15:40-15:55	PS12-3	Policies and Strategy in MAFLD: South Pacific and Polynesian View	Mohammed Eslam	Sydney
15:55-16:10	PS12-4	Policies and Strategy in MAFLD: South-East Asia View	Wah-Kheong Chan	Kuala Lumpur
16:10-16:25	PS12-5	Policies and Strategy in MAFLD: South Asia View	Shiv K. Sarin	New Delhi
16:25-16:40	PS12-6	TBA	Oidov Baatarkhuu	Ulaanbaatar
16:40-16:50		Panel Discussion & Announcement		
Closing Ceremony				Room 305
17:15-17:30				